Koers Merck & Co., Inc. Euronext Paris
Aandelen
MRK
US58933Y1055
Farmaceutische producten
Omzet 2024 * | 64,18 mld. 59,87 mld. | Omzet 2025 * | 68,68 mld. 64,07 mld. | Marktkapitalisatie | 328 mld. 306 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 19,51 mld. 18,2 mld. | Nettowinst (verlies) 2025 * | 22,25 mld. 20,75 mld. | EV/omzet 2024 * | 5,4 x |
Nettoschuld 2024 * | 18,6 mld. 17,35 mld. | Nettoschuld 2025 * | 7,28 mld. 6,79 mld. | EV/omzet 2025 * | 4,88 x |
K/w-verhouding 2024 * |
16,7
x | K/w-verhouding 2025 * |
14,5
x | Werknemers | 71.000 |
Dividendrendement 2024 * |
2,39% | Dividendrendement 2025 * |
2,53% | Vrij verhandelbaar | 70,77% |
Recentste transcriptie over Merck & Co., Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01-04-14 |
Director of Finance/CFO | 55 | 01-01-90 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01-08-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27-11-07 |
Pamela Craig
BRD | Director/Board Member | 67 | 01-09-15 |
Inge Thulin
BRD | Director/Board Member | 69 | 01-03-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+51,47% | 791 mld. | |
+40,45% | 630 mld. | |
+9,12% | 298 mld. | |
+17,40% | 246 mld. | |
+0,53% | 225 mld. | |
+10,26% | 218 mld. | |
+4,58% | 160 mld. | |
-5,54% | 156 mld. | |
-2,37% | 116 mld. |